Institutional investors include affiliates of Off the Chain Capital and Discovery Capital ManagementMINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into securities purchase agreements with certain institutional investors, including an aff

EMERYVILLE, Calif.--( BUSINESS WIRE )--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu thereof), 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock, 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of common stock and 3,200,380 Series F-3 warrants to purchase up to 3,200,380 shares of com

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 for Alzheimer’s Disease patients Proceeds expected to support Company beyond 6 month and 12 month data from the PMN310 Phase Ib study in Alzheimer’s patients TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN

MIAMI BEACH, Fla., July 26, 2024 /PRNewswire/ -- Immorta Bio Inc, a science-based longevity company dedicated to treating "Diseases of Aging and Aging as a Disease™" with personalized cellular solutions, today announced the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The IND, which was granted #30745, is to initiate a clinical trial to evaluate safety, immunogenicity, and efficacy signals of SenoVax in patients with advanced non-small cell

Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of a China domestic anti-PD-L1 mAb. The European Commission (EC) approval is based on the results of GEMSTONE-302 Phase 3 trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival and ov

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 5, 2024, to discuss the financial results and provide a business update. Investors and the general public can ac

1. 医美赛道有多火？全球最强雾化巨头强势入局 全球雾化领军企业思摩尔国际与卫光生物合作，成立中御生物，利用专业雾化透皮技术进军医美领域，推出革新性TPS无创透皮给药技术，并打造优秀药械产品组合，旨在开创无创科技美容新纪元。 2. 中国乳制品巨头布局合成生物学领域，推动绿色技术发展创新 中国乳制品巨头伊利与英国生物公司Xampla合作，利用天然聚合物胶囊技术强化乳制品营养，推动绿色创新。Xampla技术旨在替代传统塑料，应对全球塑料污染挑战。伊利致力于可持续发展，注重环保公益事业。 3. 免去上百次治疗，辉瑞血友病B基因疗法获欧盟批准 辉瑞公司宣布，欧盟委员会已授权DURVEQTIX®（一种治疗重度和中度重度血友病B的基因疗法）用于没有IX因子抑制剂或AAV血清型Rh74可检测抗体史的患者。DURVEQTIX使患者能够通过一次性剂量自行产生IX因子，从而减少了频繁静脉输注的需要。辉瑞首席国际商务官Alexandre de Germay表示，DURVEQTIX为适当的B型血友病患者提供长期出血保护，减少或消除出血，有可能改变欧盟的B型血友病护理。血友病B是一种罕见的遗传性出血性疾病，由I

近年来的临床研究表明，迷幻蘑菇中的主要精神活性分子——裸盖菇素对重度抑郁症、成瘾等多种疾病具有显著的治疗效果。它不仅起效迅速，而且效果持久，可能持续数周、数月甚至数年。然而，裸盖菇素在急性和长期作用下如何影响大脑状态仍不完全明晰。 最近，Siegel等人在Nature杂志上发表了题为Psilocybin desynchronizes the human brain的研究论文。他们通过对摄入高剂量裸盖菇素的健康志愿者进行大脑变化分析，发现裸盖菇素能使人脑的同步性丧失，为理解裸盖菇素在急性和长期影响下改变大脑功能的机制提供了新见解。 人脑是一个极其复杂的器官，包含约1000亿个神经元，这些神经元通过连接形成各种网络，以协调思想、行为和情感。为了探究裸盖菇素如何影响大脑网络，Siegel等人在研究中使用功能性磁共振成像（fMRI）技术，监测健康年轻人在摄入25毫克裸盖菇素前、期间以及摄入后3周内的大脑活动。 实验结果显示，裸盖菇素扰乱了大脑的神经通信模式，特别是在默认模式网络中，这个网络与个体的自我感、空间感和时间感相关。裸盖菇素导致了显著的神经非同步性，这种非同步性减少了网络内部的整合和网

STOCKHOLM, July 26, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products for Human Use (CHMP's) negative opinion posted today on the Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer's disease in the EU. "We are surprised and very disappointed by the CHMP's opinion posted today. Foremost the negative opinion adopted by the CHMP is sad for

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen’s Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in